ASRT: Assertio Holdings, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 71.63
Enterprise Value ($M) 36.70
Book Value ($M) 138.00
Book Value / Share 1.45
Price / Book 0.52
NCAV ($M) 22.65
NCAV / Share 0.24
Price / NCAV 3.16

Profitability (mra)
Return on Invested Capital (ROIC) -1.86
Return on Assets (ROA) -0.80
Return on Equity (ROE) -1.32

Liquidity (mrq)
Quick Ratio 1.43
Current Ratio 1.83

Balance Sheet (mrq) ($M)
Current Assets 171.06
Assets 286.42
Liabilities 148.42
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 152.07
Operating Income 30.11
Net Income -331.94
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 49.60
Cash from Investing 3.10
Cash from Financing -44.20

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-14 13G/A Continental General Insurance Co 0.00 -100.00
02-14 13G/A Armistice Capital, Llc 6.13
02-14 13G Nantahala Capital Management, LLC 8.00
02-13 13G Vanguard Group Inc 5.15 -5.32
01-26 13G BlackRock Inc. 6.90 13.40

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-11 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-19 274,992 832,855 33.02
2024-04-18 200,959 634,117 31.69
2024-04-17 236,048 823,118 28.68
2024-04-16 120,156 562,605 21.36
2024-04-15 267,989 218,055 122.90

(click for more detail)

Similar Companies
APVO – Aptevo Therapeutics Inc. ARTL – Artelo Biosciences, Inc.
ASNS – Actelis Networks, Inc. ATNF – 180 Life Sciences Corp.
ATOS – Atossa Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io